CEO SUMMARY: Many anatomic pathology groups are watching their revenue decline and margins shrink on the same or greater case volume. These trends make it imperative to have a deeper understanding of the operational and financial variables that contribute to stability in the group’s finances and pathologist compensation. One expert on the financial complexity of anatomic
Tag: Anatomic pathologySkip to articles
Anatomic pathology is about diagnosing disease through the examination of organs and tissue samples by using a microscope, or through molecular, biochemical or immunological means.
It differs from clinical pathology, where diseases are diagnosed through analyzing bodily fluids in a lab.
In anatomic pathology, a physician trained in pathology examines surgical specimens (e.g., from a biopsy). This contrasts from clinical pathology, where blood, throat cultures, and urine as sent to a lab for analysis to determine whether a patient either has or is at risk for several biological diseases.
The American Board of Pathology is one of the primary certification organizations for anatomic pathologists. To be certified in anatomic pathology, a physician must complete four years of medical school and three years of residency. To be certified in both anatomic and clinical pathology, a physician must do four years of residency.
Anatomic pathologists typically work in hospitals, and pathology in general is most times practiced in hospitals and academic medical centers, where research is being conducted.
CEO SUMMARY: By its name alone, the National Correct Coding Initiative (NCCI) Policy Manual implies that it will be accurate and consistent with other coding initiatives. But nine groups representing various clinical laboratories say NCCI guidelines that the federal Centers for Medicare and Medicaid Services issued in December and implemented on Jan. 1 are inconsistent
Our Editor-In-Chief just finished the daunting task of confirming 125 speakers for more than 80 sessions for our 24th annual Executive War College on Lab and Pathology Management. It is our biggest conference ever! These facts are significant to you for an important reason.
The planning phase for an Executive War College requires requires hundreds of
THERE IS A NEW FAVORITE WORD WALL STREET ANALYST USE when they want to describe an industry that is going to experience tough times that will make it difficult for companies to grow and remain profitable. That word is “headwinds” and it can aptly be applied to the multiple tough challenges that are about to
CEO SUMMARY: At Northwell Health, the clinical laboratory team has been busy building and opening two new, large laboratory facilities. First to open was the lab in Little Neck, Queens, a shared lab with NYC Health and Hospitals. This lab will handle 36 million tests annually. The second lab to open is Northwell’s new core
CEO SUMMARY: When Ascension Wisconsin wanted one pathology group to serve its needs statewide, North Shore Pathologists responded to the request for proposal by focusing on how pathologists can improve patient care through a patient-centered model. Other pathology groups responded with proposals that emphasized the financial aspects of the relationship. Focusing on patient care won
BIGGER PATHOLOGY GROUPS AND METROWIDE OR STATEWIDE COVERAGE will be major characteristics in the anatomic pathology profession as healthcare continues to transform in new ways. That is why the reasons for the substantial growth in case volume and revenue at North Shore Pathologists (NSP) in Milwaukee should be studied by pathology groups everywhere.
It was a practice
By any measure, it is tougher today for clinical laboratories and anatomic pathology groups to generate the revenue needed to deliver state-of-the-art diagnostic testing services while remaining financially viable. Four recent trends prove the point.
First, every year, the Medicare program and private health insurers are cutting the prices they pay for medical laboratory tests.
CEO SUMMARY: This will be one of the most challenging years facing the clinical lab industry since the early 1990s. The CMS scheme to collect private payer lab test prices and use that data to set Medicare clinical laboratory test prices is proving to be an indiscriminate tool that is poised to undermine the financial integrity of many labs,
CEO SUMMARY: This will be one of the most challenging years facing the clinical lab industry since the early 1990s, when closed panel HMOs were the disruptive force that generated deep cuts in lab test prices. However, unlike HMOs of that era, the CMS scheme to collect private payer lab test prices and use that